Vertex Pharmaceuticals (VRTX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $4.73
- EPS estimate
- $4.74
- EPS surprise
- −0.23%
- Revenue surprise
- +3.25%
- Revenue
- $3.3B
- Revenue estimate
- $3.2B
- Reported
- Aug 3, 2026
Vertex Pharmaceuticals reported Q2 2026 results on August 3, 2026. Earnings per share came in at $4.73, just below the $4.74 estimate by 0.23%. Revenue was $3.3 billion, above the $3.2 billion consensus. Compared with Q2 2025, EPS rose about 5% from $4.52 and revenue rose about 14% from $2.9 billion.
Revenue grew steadily, from $8.9 billion in 2022 to $9.9 billion in 2023, $11.0 billion in 2024 and $12.0 billion in 2025. Q2 2026 set the revenue high in the table. Annual EPS was $14.89 in 2022 and $15.22 in 2023, then fell to $0.29 in 2024. That year included a loss of $12.83 per share in Q2 2024, the only loss in the table. Annual EPS recovered to $18.41 in 2025. First-half 2026 EPS of $9.20 is about 7% above a year earlier. The EPS high was $5.03, in Q4 2025. Over the last 20 quarters, Vertex topped the EPS estimate 14 times. Its largest beat was 16.87%, in Q1 2024.
Vertex reported Q3 between October 27 and November 6 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether revenue growth carries on.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 3, 2026 | $4.74 | $4.73 | −0.23% | $3.3B | SEC |
| Q1 2026 | May 4, 2026 | $4.24 | $4.47 | +5.35% | $3.0B | SEC |
| Q4 2025 | Feb 12, 2026 | $5.11 | $5.03 | −1.58% | $3.2B | SEC |
| Q3 2025 | Nov 3, 2025 | $4.57 | $4.80 | +4.96% | $3.1B | SEC |
| Q2 2025 | Aug 4, 2025 | $4.29 | $4.52 | +5.40% | $2.9B | SEC |
| Q1 2025 | May 5, 2025 | $4.32 | $4.06 | −5.95% | $2.8B | SEC |
| Q4 2024 | Feb 10, 2025 | $4.02 | $3.98 | −0.90% | $2.9B | SEC |
| Q3 2024 | Nov 4, 2024 | $4.08 | $4.38 | +7.41% | $2.8B | SEC |
| Q2 2024 | Aug 1, 2024 | −$11.63 | −$12.83 | −10.36% | $2.6B | SEC |
| Q1 2024 | May 6, 2024 | $4.07 | $4.76 | +16.87% | $2.7B | SEC |
| Q4 2023 | Feb 5, 2024 | $4.07 | $4.20 | +3.27% | $2.5B | SEC |
| Q3 2023 | Nov 6, 2023 | $3.93 | $4.08 | +3.72% | $2.5B | SEC |
| Q2 2023 | Aug 1, 2023 | $3.86 | $3.89 | +0.80% | $2.5B | SEC |
| Q1 2023 | May 1, 2023 | $3.01 | $3.05 | +1.23% | $2.4B | SEC |
| Q4 2022 | Feb 7, 2023 | $3.53 | $3.76 | +6.50% | $2.3B | SEC |
| Q3 2022 | Oct 27, 2022 | $3.61 | $4.01 | +11.00% | $2.3B | SEC |
| Q2 2022 | Aug 4, 2022 | $3.47 | $3.60 | +3.64% | $2.2B | SEC |
| Q1 2022 | May 5, 2022 | $3.57 | $3.52 | −1.38% | $2.1B | SEC |
| Q4 2021 | Jan 26, 2022 | $3.29 | $3.37 | +2.53% | $2.1B | SEC |
| Q3 2021 | Nov 2, 2021 | $3.09 | $3.56 | +15.22% | $2.0B | SEC |
Quarterly revenue
Frequently asked questions
When did Vertex Pharmaceuticals (VRTX) last report earnings?
Vertex Pharmaceuticals last reported on Aug 3, 2026, covering fiscal Q2 2026.
Did VRTX beat earnings estimates?
No. Vertex Pharmaceuticals reported EPS of $4.73 for Q2 2026 against a $4.74 estimate — a 0.23% miss.
How much revenue did VRTX report last quarter?
Vertex Pharmaceuticals reported $3.3B in revenue for Q2 2026, against a consensus estimate of $3.2B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.